MedTrace Logo

BLADE: Comparison of Once Daily Lopinavir/Ritonavir to Lopinavir/Ritonavir BID Dosing in HIV-Infected Subjects

NCT00388492 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 45

Last updated 2007-01-11

No results posted yet for this study

Summary

The goal of this study is to evaluate the proportion of subjects both antiretroviral experienced and virologically suppressed on lopinavir/ritonavir (LPV/r)400/100mg twice daily who maintain viral suppression after switching to lopinavir/ritonavir (LPV/r)800/200mg once daily.

The hypothesis for this study is that the majority of subjects will remain virologically suppressed with once daily dosing versus twice daily dosing and therefore quality of life will be improved with the once daily dosing of lopinavir/ritonavir (LPV/r)800/200mg.

Conditions

  • HIV Infections

Sponsors & Collaborators

  • Bellos, Nicholaos C., M.D.

    lead INDIV

Principal Investigators

  • Nicholaos C. Bellos, MD · Nicholaos C. Bellos, MD

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00388492 on ClinicalTrials.gov